Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME study of gilteritinib in advanced solid tumors
NCT02456883Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gilteritinib in solid tumor (advanced stage), sponsored by Astellas Pharma. Primary endpoints: Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): AUCtau, Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): Cmax and 20 more. Started Mar 2016; status: completed.
02
Drugs
gilteritinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02456883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456883.